MicroPort CRM Launches MicroPort Academy CRM, an Education Website Dedicated to Healthcare Professionals and Designed by Experts in Cardiac Pacing
16.2.2021 12:00:00 EET | Business Wire | Press release
MicroPort CRM, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM. The website is dedicated to Healthcare Professionals who want to enhance their knowledge about cardiac pacing therapy and the functionality of MicroPort CRM products. It was developed in collaboration with Stimuprat Editions, and designed by world-renowned experts in cardiac pacing.
MicroPort Academy CRM provides personalized and interactive training plans, ranging from diagnosis of ECG tracings to techniques of pacemaker implantation, programming simulation and troubleshooting. The site is open to health care professionals worldwide, and is aimed at both beginners and experienced people in cardiac rhythm management.
“Providing additional training to healthcare professionals to support them in better understanding and use of our products has always been part of our mission”, said Benoît Clinchamps, President of MicroPort CRM. “Our goal is to provide the highest quality training and ensure it is accessible to everyone, all over the world. To launch this website as part of our mission, we relied on electrophysiologists who are not only experts, but who are also guided by their passion to share their experience and knowledge.”
Prof. Pierre Bordachar, Electrophysiologist from University Hospital of Bordeaux and Medical Advisor at Stimuprat Editions, stated, “There are no better trainings than those based on real cases. This is why we have paid particular attention to building courses around real world situations, illustrated by numerous ECG tracings, videos, and programming simulations. I have no doubt that MicroPort Academy CRM brings a unique experience for cardiac pacing online training.”
MicroPort Academy CRM will continue to be enriched with new modules, and to reflect both the evolution of practices and those of products. Cardiac Rhythm Management is an area where innovative solutions and technologies are emerging at a rapid pace, and where distance digital training brings all the power of their flexibility and efficiency.
For more information, please visit www.microportacademycrm.com
About MicroPort CRM
MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), whose world headquarters are in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic.
For more information, please refer to www.microport.com and www.microportacademycrm.com
About Stimuprat Editions
Stimuprat Editions, created by experts in the field of cardiology training, has been developing innovative and practical educational content for many years, allowing in-depth and unique learning experience.
Stimuprat Editions specializes in publishing books and designing digital training courses in cardiology for healthcare professionals. It offers free access on www.cardiocases.com, the largest collection of clinical cases and tracings in cardiac rhythmology, and designs training and simulation platforms on implantable device therapies for the biomedical industry.
Its unique expertise makes it the benchmark for training in the field of "Cardiac Rhythm Management".
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005513/en/
Contact information
Joël Courville – MicroPort CRM
VP Strategy and Corporate Affairs
joel.courville@crm.microport.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release
RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom